(Research Article)

1

# IJPSR (2017), Vol. 8, Issue 1





Received on 01 July, 2016; received in revised form, 18 September, 2016; accepted, 26 September, 2016; published 01 January, 2017

# SELF MICRO EMULSIFYING DRUG DELIVERY SYSTEM FOR COMBINATION OF HYDROPHILIC AND LIPOPHILIC DRUGS

Siya D. Sinai Kunde<sup>\*</sup> and Shilpa P. Bhilegaonkar

Department of Pharmaceutics, PES' Rajaram and Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, Goa, India.

### Keywords:

Amoxicillin, Clarithromycin, Self Micro Emulsifying Drug Delivery System (SMEDDS), Solubility, Bioavailability

#### Correspondence to Author: Siya D. Sinai Kunde

PES's Rajaram and Tarabai Bandekar College of Pharmacy, near Farmagudi Police Outpost, Farmagudi, Ponda, Goa, India

Email: siya.kunde14@gmail.com

**ABSTRACT:** Improvement in the bioavailability of poorly soluble drugs is one of the challenges faced in the formulation development of the drugs. One of the most admirable and viable formulation approaches for this is self micro emulsifying drug delivery system (SMEDDS). A combination of clarithromycin and amoxicillin has been proved effective for treatment of *H. pylori* which are available only in tablet dosage form. Hence, the aim of the present study was to prepare SMEDDS of amoxicillin and clarithromycin for better patient compliance. SMEDDS were prepared using Peceol, Cremophor EL and Transcutol as oil, surfactant and co-surfactant respectively. Prepared SMEDDS were evaluated for particle size, zeta potential, water dispersion properties, saturation solubility and *in-vitro* drug release. Dilution study by visual observation showed that there was spontaneous micro emulsification and no sign of phase separation. Study concluded that SMEDDS can be an effective alternative for tablet therapy with enhanced dissolution rate and bioavailability.

**INTRODUCTION:** With the advent of drug design, various molecules have been created which have a potential for therapeutic action. But most of the chemical entities are of high molecular weight and belong to biopharmaceutical classification system (BCS) – II, with poor aqueous solubility and high membrane permeability. Hence, the bioavailability of the drugs is hindered by low solubility which leads to low dissolution and limits absorption which ultimately leads to high inter-and intra-subject variability and lack of dose proportionality.<sup>1</sup>



Even though many modified drugs are available, few therapies require a combination drug regiment for effective treatment in high concentration which may not belong to the same class of BCS. In such cases, it is very difficult to combine the drugs together to improve patient compliance. One such example is treatment of Helicobacter pylori infection.

*H. pylori*, it is a spiral-shaped bacterium attached to or just above the gastric mucosa. These organisms persist in the stomach indefinitely and may not cause clinical illness for many years after infection. *H. pylori* infection is chronic and if acquired remains life long, unless eradicated by antibiotics.<sup>2</sup> Antibiotics preferred for the treatment of h. *pylori* are clarithromycin and amoxicillin which has proved to be highly effective in the eradication of *H. pylori*. The current therapy includes tablet dosage forms in high doses which may cause inconvenience to the patient and can also cause dose dumping and toxicity. There is no combination dosage form available for the same which can help in patient compliance and convenience to patient.<sup>3, 4</sup>

Self-emulsifying drug delivery systems (SMEDDS) are isotropic mixtures of oil, surfactant, cosurfactant and drug. It offers numerous advantages such as spontaneous formation, thermodynamic stability, improved bioavailability and feasibility for preparation. Enhanced solubility and improved bioavailability are amongst the main advantages of SMEDDS.<sup>5</sup>

As mentioned above, to prepare a combination dosage form of both the antibiotics, the main hurdle is the nature of the drugs, where in clarithromycin is lipophilic and amoxicillin is hydrophilic.

Here we have made and attempt to apply the principles of SMEDDS to combined delivery of hydrophilic and lipophilic drugs by using SMEDDS excipients as oil, surfactant, and co-surfactant. The prepared systems were evaluated for particle size, zeta potential, water dispersion properties, saturation solubility, assay and *in-vitro* drug release by filling in hard gelatine capsule shells. <sup>6</sup>

# **MATERIALS AND METHODS:**

**Materials Used:** Amoxicillin Trihydrate and Clarithromycin were obtained as a gift sample from Unichem Laboratories, Pilerne, Goa. Maisine 35-1, Peceol, Labrafil and Transcutol P was acquired from Gattefosse India. Cremophor EL, Cremophor RH 40 was obtained as a gift sample from BASF India, Mumbai. Corn oil and Olive oil were obtained from Genuine Chem, Mumbai. Tween 20, PEG 400 and Ethanol were obtained from SD fine chemicals, Mumbai. Cashew oil was purchased from the local suppliers.

**Saturation Solubility Analysis:** Pre formulation solubility analysis was done to select the vehicle in which drug is more soluble and suitable for formulation of SMEDDS. The solubility of amoxicillin and clarithromycin in various oils, surfactants and co-surfactants procured was determined by adding excess amount of the drugs into 1 ml of each vehicle in a centrifuge tube, followed by mixing at around 200 rpm in an orbital shaker (Electrolab, Mumbai) at room temperature for 24 h. The samples were centrifuged at 3000 rpm for 10 min to remove the excess drugs after which the concentration of amoxicillin and clarithromycin in the supernatant was measured by UV Spectrophotometer (Shimadzu UV 1800) after appropriate dilution with methanol for amoxicillin and 0.1 N HCl with FC reagent for clarithromycin (since clarithromycin showed very low detection in the UV region, it was detected in the visible region using a reagent).<sup>7</sup>

Preparation of SMEDDS of Amoxicillin and **Clarithromycin:** А series of **SMEDDS** formulation were carried out by using Cremophor EL and Transcutol P as S/CoS combination and Peceol as oil. In all formulations the level of amoxicillin and clarithromycin was kept constant (i.e. 250 mg and 125 mg respectively) and the varying ratio of oil, surfactant and co-surfactant were added to the vial. Then the components were mixed by gentle stirring and sonication and were heated at 40°C on a magnetic stirrer until the drugs was perfectly dissolved.<sup>8</sup> The mixture was stored at room temperature until further use. The various formulation ratios are given in Table 1.

Formulation	S: CoS	Oil	Surfactant	Co-
	ratio	(mg)	( <b>mg</b> )	surfactant
				( <b>mg</b> )
F1	1:1	100	450	450
F2	1:1	200	400	400
F3	1.5:1	100	540	360
F4	2:1	100	600	300

# **Characterization and Evaluation:**

**1.1 Solubility Enhancement Studies:** The solubility of SMEDDS and pure drugs in various solvents (water, 0.1N HCL pH 1.2) was determined by adding a fixed dose of amoxicillin and clarithromycin (i.e. 250 mg and 125 mg) into 1 ml of each vehicle in a centrifuge tube, followed by mixing at around 200 rpm in an orbital shaker at room temperature for 24 h. The samples were centrifuged at 3000 rpm for 5 min to remove the excess drugs after which the concentration of amoxicillin and clarithromycin in the supernatant was measured by UV Spectrophotometer after appropriate dilution with the required solvent.

**1.2 Determination of Particle Size and Zeta potential:** Globule size and polydispersity index of the amoxicillin and clarithromycin SMEDDS were determined by particle size analyser. Data analysis was conducted using software package provided by manufacturer. The emulsion stability is directly related to the magnitude of the surface charge. The zeta potential of the diluted SMEDDS formulation was measured using a (Zetasizer instrument). The SMEDDS were diluted with a ratio of 1:10 v/v with distilled water and mixed for 1m using a cyclomixer.

**1.3 Self-Emulsification Assessment:** Evaluation of the self-emulsifying properties of SMEDDS formulations was performed by visual assessed using the grading system given in **Table 2**. In brief, different compositions were categorized on speed of emulsification, clarity and apparent stability of the resultant emulsion. Visual assessment was performed by drop wise addition of the SMEDDS into 250 ml of distilled water. This was done in a glass beaker at room temperature, and the contents were gently stirred magnetically at ~100 rpm.

TABLE 2: VISUAL ASSESSMENT OF EFFICIENCY OFSELF-MICRO EMULSIFICATION

Grade	Dispersibility	Time for self- emulsification (min)
А	Rapidly forming clear or	<1
	bluish appearance	
В	Rapidly forming but has less	1-2
	clear bluish white appearance	
С	Bright white milky appearance	2-3
D	Dull greyish white emulsion	>3
	with slightly oily appearance	
E	Poor emulsification with large	>3
	oil droplets on the surface	
	on dropiets on the surface	

**1.4** *In- vitro* **Drug Release Studies:** The *In-vitro* dissolution studies were carried out by using paddle type USP dissolution apparatus II. Dissolution test was done on SMEDDS capsules containing the drug equivalent to 250 mg and 125 mg of pure drugs. Dissolution was carried out in 900 ml 0.1 N HCl at 50 rpm at temperature of  $37 \pm 0.5^{\circ}$ C. Sample aliquots (10ml) of dissolution medium were withdrawn at different time intervals of 30, 60, 90 and 120 min. Necessary dilutions were made with 0.1 N HCl. The samples were assayed spectrometrically at 229.2 nm and 761.5 nm respectively.

1.5 Drug Content: 2 ml of SMEDDS was taken. 1 ml of which was added to a 10 ml volumetric flask and volume was made up using methanol. Further, 1 ml from solution was withdrawn and transferred to a 10 ml flask and volume was made up using methanol. UV absorbance was taken at 230 nm. The remaining 1 ml was added to 10 ml volumetric flask and volume was made with 0.1 N HCl. 1 ml from solution was withdrawn and transferred to a 10 ml volumetric flask containing 2 ml of FC reagent (1: 2 ratio) and 20 % Na2CO3 and volume was made up using 0.1 N HCl. Visible absorbance was taken at 761.5 nm. Blank emulsions containing methanol and 0.1 N HCl was used as the blanks respectively. The values obtained were used to calculate the % drug contents.

# **RESULTS AND DISCUSSION:**

Saturation Solubility Analysis: The components used in the system showed high solubilization capacity for the drug, ensuring the solubilization of the drug in the resultant dispersion and therefore avoiding precipitation of drug on dilution. Results from solubility studies are reported in Fig.1, 2 and 3 and as seen, combination of peceol, cremophor EL and transcutol P showed the highest solubilization capacity for amoxicillin and clarithromycin which were selected as oil. surfactant and co- surfactant, respectively.





International Journal of Pharmaceutical Sciences and Research



FIG. 3: SOLUBILITY IN CO SURFACTANTS

It was seen that amoxicillin and clarithromycin showed high solubility in oils, surfactants and co surfactants. From the data obtained cremophor EL and transcutol P was selected as the S/CoS system and peccol as the oil. The concentrations of the S/CoS systems and oil were varied keeping the dose of the amoxicillin and clarithromycin constant i.e. 250 mg and 125 mg respectively. At low concentrations of amoxicillin and clarithromycin, a clear solution was obtained but with the increase in the concentration to 250 mg and 125 mg respectively, a milky emulsion was formed.

# **Characterization and Evaluation:**

**2.1 Solubility Enhancement Studies:** Solubility of pure drug and SMEDDS were evaluated and amoxicillin and clarithromycin SMEDDS showed considerable enhancement in solubility as compared to the pure drug.

TABLE 3: SOLUBILITY COMPARISON BETWEEN PURE DRUGS AND SMEDDS

Sr.no.	Buffers used	Solubility in mg/mL			
		Pure drug		SN	IEDDS
		Amoxicillin	Clarithromycin	Amoxicillin	Clarithromycin
1.	0.1N HCl pH 1.2	4.293	15.878	9.874	27.91
2.	Water	4.395	17.129	9.695	31.187

2.2 Particle size Zeta **Potential** and Determination: The droplet size distribution of various formulations is given in Table 4. It was observed that formulation F1 having highest proportion of surfactant (450 mg) and co-surfactant (450 mg) and oil (100 mg) shows the lowest mean particle diameter, where formulation F2 having lowest proportion of surfactants shows higher mean particle size. Thus an increase in the oil phase resulted in proportional increase in particle size because of simultaneous decrease in the S/CoS proportion. Addition of surfactants to the microemulsion system causes the interfacial film to stabilize and condense, while the addition of cosurfactant causes the film to expand.

TABLE 4: PARTICLE SIZE AND ZETA POTENTIALDETERMINATION OF SMEDDS

Parameters	Formulation		
	F1	F2	
Polydispersity index	1.646	1.832	
Particle size (nm)	62.90	59.76	
Dispersion time (min)	2-3	2-3	
Zeta potential (mV)	79.55	67.61	

Particle size distribution is depicted in **Fig.4**. Formulation F1 and F2 have zeta potential 79.55 mV and 67.61 mV respectively. The zeta potential indicates that there is no flocculation of particles and thus the microemulsion was stable.



2.3 Self-Emulsification Assessment: It was seen that an increase in the proportion of cremophor EL, the composition resulted in decreasing selfemulsification time. The decrease in selfemulsification time can be assumed to be due the relative increase in surfactant concentration, leading to decreased viscosity of the formulation. The S/CoS ratio of 1:1 was kept constant for the initial formulation study. However, with an increase in the surfactant ratio, it was found that the resultant dispersion showed precipitation and thus was not stable. Transcutol P when added as a cosurfactant seems to increase the solubilization capacity of the vehicle.

2.4 In-vitro drug release: The in-vitro drug release studies were performed and the % drug release graph was plotted against time. In-vitro drug release profile of SMEDDS formulation F1 and F2 are given in Fig.5 and Fig. 6. Based on drug release, comparison studies of F1 and F2 was done, it was observed that the drug release from SMEDDS of formulation F1 showed significantly higher release compared formulation F2. There was 99% release of either of the drugs from formulation F1 within 2h. It was suggested that the SMEDDS formulation resulted in spontaneous formation of a microemulsion with small droplet size which permitted a faster rate of drug release into the aqueous phase. Thus, this greater availability of dissolved amoxicillin and clarithromycin from the SMEDDS formulation could lead to higher absorption and oral bioavailability.







**2.5 Drug Content:** Formulation F1 and F2 were assayed spectrophotometrically for the drug content at the wavelength 229.5 nm and 761.5 nm for amoxicillin and clarithromycin respectively with proper dilution of formulations taking methanol and 0.1 N HCl with FC reagent. Results of content

uniformity were shown in Table no.5. Formulation F1 had highest content uniformity 97% of amoxicillin and 98% of clarithromycin which was higher compared to F2.

TABLE 5: DRUG CONTENT OF AMOXICILLIN AND<br/>CLARITHROMYCIN IN SMEDDS

Parameters	Amoxicillin		Clarithromycin	
-	F1	F2	F1	F2
Drug content	121.57 mg	115.08mg	61.33mg	56.78 mg
Percentage	97.26%	92.06%	98.13%	90.84%
yield				

From the results obtained above it can be seen that there was a marked increase in the solubility and dissolution of combined systems of hydrophilic and lipophilic drugs. The reason for the same can be solubilisation of lipophilic drug into oil and S/CoS system and consecutive emulsification to sub micron size and for hydrophilic drugs it can be wetting by modified surfactant and co surfactant system which enhances the solubility and dissolution.

**CONCLUSION:** An optimized amoxicillin and clarithromycin loaded formulation consisting of 1:1 ratio of peceol (100 mg), cremophor EL (450 mg) and transcutol P (450 mg) offers the advantage as a good system for solubilization of amoxicillin trihydrate and clarithromycin.

From the above studies it can be concluded that SMEDDS is not only a better alternative for lipophilic drugs but can also be effectively used for combinations of hydrophilic and lipophilic drugs.

## **REFERENCES:**

- Kalepu S, Manthina M., Padavala V: Oral lipid-based drug delivery systems – an Overview. Acta Pharm Sin B 2013; 3(6):361-372.
- Siddhalingam R., Chidambaram K: *Helicobacter pylori* Current Therapy and Future Therapeutic Strategies. Bruna Maria Roesler (Eds.); 284- 302.
- Olokoba A.B., Obateru O.A., Bojuwove M.O: *Helicobacter pylori* Eradication Therapy: A Review of Current Trends. Niger Med J. 2013; 54(1):1–4.
- Zhuang X., Tian X., Zheng Y., Lan N., Liu L., Zhang R., Liu Y: Formulation and physicochemical characterisation of a novel self- microemulsifying delivery system as hydrotropic and solubilising agent for penfluridol. Procedia Engineering 2011; 18:59 – 65.
- Rocco Maurizio Zagaria, Marco Romanob, Veronica Ojetti, Reinhold Stockbruggerd, Sergio Gullini, Bruno Annibalef, Fabio Farinati, EnzoIerardi, Giovanni Maconii, Massimo Ruggej, Carlo Calabresea, Francesco Di Mariok, Francesco Luzzal, Stefano Pretolanim, AntonellaSavion, Giovanni Gasbarrinic, Michele Caselli: Guidelines for the management of

*Helicobacter pylori* infection Italy: The III Working Group Consensus Report 2015. Digest Liver Dis, 2015; 47:903– 912.

 Singh A. K., Chaurasiya A, Singh M: Exemestane Loaded Self-microemulsifying Drug Delivery System (SMEDDS): Development and Optimization; AAPS Pharma Science Tech 2008; 2:22-34.

- Suryavanshi M., Kondawar M: Formulation and Evaluation of Solid Self Micro Emulsifying Drug Delivery System. Der Pharmacia Sinica 2014; 5(5):27-35.
- Bandivadekar M. M., Pancholi S. S., Shelke N: Preparation and Characterisation of Solid Self Micro Emulsifying Drug Delivery System by Adsorbent Technique to Improve Dissolution Profile of Poorly Aqueous Soluble Drug Ramipril. IRJP 2011; 2(6):85-90.

#### How to cite this article:

Kunde SDS and Bhilegaonkar SP: Self micro emulsifying drug delivery system for combination of hydrophilic and lipophilic drugs. Int J Pharm Sci Res 2017; 8(1): 191-96.doi: 10.13040/IJPSR.0975-8232.8(1).191-96.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to ANDROID OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)